Abstract
This article has been corrected. The original version (PDF) is appended to this article as a Supplement.
Osteoporosis is a common systemic skeletal disorder resulting in bone fragility and increased fracture risk. However, management of osteoporosis and fracture prevention strategies are often not addressed by primary care clinicians, even in older patients with recent fractures. Evidence-based screening strategies will improve identification of patients who are most likely to benefit from drug treatment to prevent fracture. In addition, careful consideration of when pharmacotherapy should be started and choice of medication and duration of treatment will maximize the benefits of fracture prevention while minimizing potential harms of long-term drug exposure.
References
- 1.
Wright NC ,Looker AC ,Saag KG ,et al . The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res. 2014;29:2520-6. [PMID: 24771492] doi:10.1002/jbmr.2269 CrossrefMedlineGoogle Scholar - 2.
U.S. Preventive Services Task Force . Screening for osteoporosis: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2011;154:356-64. [PMID: 21242341]. doi:10.7326/0003-4819-154-5-201103010-00307 LinkGoogle Scholar - 3. National Osteoporosis Foundation. 2014 clinician's guide to prevention and treatment of osteoporosis. Accessed at www.nof.org/news/nofs-clinicians-guide-published-by-osteoporosis-international/ on 16 June 2017. Google Scholar
- 4. International Society for Clinical Densitometry. 2015 ISCD Official Positions—Adult. Accessed at www.iscd.org/official-positions/2015-iscd-official-positions-adult/ on 15 August 2013. Google Scholar
- 5. Looker AC, Frenk SM. Percentage of adults aged 65 and over with osteoporosis or low bone mass at the femur neck or lumbar spine: United States, 2005-2010. Acceesed at www.cdc.gov/nchs/data/hestat/osteoporsis/osteoporosis2005_2010.htm on 18 April 2017. Google Scholar
- 6. National Committee for Quality Assurance. Osteoporosis testing and management in older women. Accessed at www.ncqa.org/report-cards/health-plans/state-of-health-care-quality/2016-table-of-contents/osteoporosis on 5 May 2017. Google Scholar
- 7.
Doherty DA ,Sanders KM ,Kotowicz MA ,Prince RL . Lifetime and five-year age-specific risks of first and subsequent osteoporotic fractures in postmenopausal women. Osteoporos Int. 2001;12:16-2. [PMID: 11305078] CrossrefMedlineGoogle Scholar - 8.
Camacho PM ,Petak SM ,Binkley N ,et al . American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis—2016. Endocr Pract. 2016;22:1-42. [PMID: 27662240] doi:10.4158/EP161435.GL CrossrefMedlineGoogle Scholar - 9.
Cadarette SM ,McIsaac WJ ,Hawker GA ,et al . The validity of decision rules for selecting women with primary osteoporosis for bone mineral density testing. Osteoporos Int. 2004;15:361-6. [PMID: 14730421] CrossrefMedlineGoogle Scholar - 10.
Leslie WD ,Lix LM ,Johansson H ,Oden A ,et al ;Manitoba Bone Density Program . Selection of women aged 50-64 yr for bone density measurement. J Clin Densitom. 2013;16:570-8. [PMID: 23452870] doi:10.1016/j.jocd.2013.01.004 CrossrefMedlineGoogle Scholar - 11. Centre for Metabolic Bone Diseases. FRAX WHO fracture risk assessment tool. Accessed at www.shef.ac.uk/FRAX/ on 15 June 2017. Google Scholar
- 12.
Crandall CJ ,Larson J ,Gourlay ML ,et al . Osteoporosis screening in postmenopausal women 50 to 64 years old: comparison of US Preventive Services Task Force strategy and two traditional strategies in the Women's Health Initiative. J Bone Miner Res. 2014;29:1661-6. [PMID: 24431262] doi:10.1002/jbmr.2174 CrossrefMedlineGoogle Scholar - 13.
Watts NB ,Adler RA ,Bilezikian JP ,et al ;Endocrine Society . Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:1802-22. [PMID: 22675062] doi:10.1210/jc.2011-3045 CrossrefMedlineGoogle Scholar - 14.
Adler RA ,Tran MT ,Petkov VI . Performance of the Osteoporosis Self-assessment Screening Tool for osteoporosis in American men. Mayo Clin Proc. 2003;78:723-7. [PMID: 12934782] CrossrefMedlineGoogle Scholar - 15. Diem SJ, Peters KW, Gourlay ML, et al. Screening for osteoporosis in older men: operating characteristics of proposed strategies for selecting men for BMD testing. J Gen Intern Med [Forthcoming]. Google Scholar
- 16.
Gourlay ML ,Fine JP ,Preisser JS ,et al ;Study of Osteoporotic Fractures Research Group . Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med. 2012;366:225-33. [PMID: 22256806] doi:10.1056/NEJMoa1107142 CrossrefMedlineGoogle Scholar - 17.
Gourlay ML ,Overman RA ,Fine JP ,et al ;Osteoporotic Fractures in Men (MrOS) Research Group . Time to osteoporosis and major fracture in older men: The MrOS Study. Am J Prev Med. 2016;50:727-36. [PMID: 26821835] doi:10.1016/j.amepre.2015.11.015 CrossrefMedlineGoogle Scholar - 18. ClinRisk. QFracture-2016 risk calculator. Accessed at www.qfracture.org/ on 1 June 2016. Google Scholar
- 19. Garvan Institute of Medical Research. Bone fracture risk calculator. garvan org au/bone-fracture-risk. Accessed at www.garvan.org.au/bone-fracture-risk on 1 June 2016. Google Scholar
- 20.
Kanis JA ,Hans D ,Cooper C ,et al ;Task Force of the FRAX Initiative . Interpretation and use of FRAX in clinical practice. Osteoporos Int. 2011;22:2395-411. [PMID: 21779818] doi:10.1007/s00198-011-1713-z CrossrefMedlineGoogle Scholar - 21.
Collins GS ,Michaëlsson K . Fracture risk assessment: state of the art, methodologically unsound, or poorly reported?. Curr Osteoporos Rep. 2012;10:199-207. [PMID: 22688862] doi:10.1007/s11914-012-0108-1 CrossrefMedlineGoogle Scholar - 22.
van den Bergh JP ,van Geel TA ,Lems WF ,Geusens PP . Assessment of individual fracture risk: FRAX and beyond. Curr Osteoporos Rep. 2010;8:131-7. [PMID: 20563901] doi:10.1007/s11914-010-0022-3 CrossrefMedlineGoogle Scholar - 23.
Rubin KH ,Friis-Holmberg T ,Hermann AP ,Abrahamsen B ,Brixen K . Risk assessment tools to identify women with increased risk of osteoporotic fracture: complexity or simplicity? A systematic review. J Bone Miner Res. 2013;28:1701-17. [PMID: 23592255] doi:10.1002/jbmr.1956 CrossrefMedlineGoogle Scholar - 24.
Ensrud KE ,Lui LY ,Taylor BC ,et al ;Study of Osteoporotic Fractures Research Group . A comparison of prediction models for fractures in older women: is more better?. Arch Intern Med. 2009;169:2087-94. [PMID: 20008691] doi:10.1001/archinternmed.2009.404 CrossrefMedlineGoogle Scholar - 25.
Crandall CJ ,Larson JC ,Watts NB ,et al . Comparison of fracture risk prediction by the US Preventive Services Task Force strategy and two alternative strategies in women 50-64 years old in the Women's Health Initiative. J Clin Endocrinol Metab. 2014;99:4514-22. [PMID: 25322268] doi:10.1210/jc.2014-2332 CrossrefMedlineGoogle Scholar - 26.
Ensrud KE ,Taylor BC ,Peters KW ,et al ;Osteoporotic Fractures in Men Study Group . Implications of expanding indications for drug treatment to prevent fracture in older men in United States: cross sectional and longitudinal analysis of prospective cohort study. BMJ. 2014;349:g4120. [PMID: 24994809] doi:10.1136/bmj.g4120 CrossrefMedlineGoogle Scholar - 27.
Ettinger B ,Ensrud KE ,Blackwell T ,et al ;Osteoporotic Fracture in Men (MrOS) Study Research Group . Performance of FRAX in a cohort of community-dwelling, ambulatory older men: the Osteoporotic Fractures in Men (MrOS) study. Osteoporos Int. 2013;24:1185-93. [PMID: 23179575] doi:10.1007/s00198-012-2215-3 CrossrefMedlineGoogle Scholar - 28.
Montori VM ,Shah ND ,Pencille LJ ,et al . Use of a decision aid to improve treatment decisions in osteoporosis: the osteoporosis choice randomized trial. Am J Med. 2011;124:549-56. [PMID: 21605732] doi:10.1016/j.amjmed.2011.01.013 CrossrefMedlineGoogle Scholar - 29.
Ensrud KE . Epidemiology of fracture risk with advancing age. J Gerontol A Biol Sci Med Sci. 2013;68:1236-42. [PMID: 23833201] doi:10.1093/gerona/glt092 CrossrefMedlineGoogle Scholar - 30.
Hill KD ,Hunter SW ,Batchelor FA ,Cavalheri V ,Burton E . Individualized home-based exercise programs for older people to reduce falls and improve physical performance: A systematic review and meta-analysis. Maturitas. 2015;82:72-84. [PMID: 25989701] doi:10.1016/j.maturitas.2015.04.005 CrossrefMedlineGoogle Scholar - 31.
Michael YL ,Whitlock EP ,Lin JS ,et al ;US Preventive Services Task Force . Primary care-relevant interventions to prevent falling in older adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2010;153:815-25. [PMID: 21173416]. doi:10.7326/0003-4819-153-12-201012210-00008 LinkGoogle Scholar - 32.
Moyer VA ;U.S. Preventive Services Task Force . Prevention of falls in community-dwelling older adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157:197-204. [PMID: 22868837] LinkGoogle Scholar - 33.
Institute of Medicine . Dietary reference intakes for calcium and vitamin D. Washington, DC: National Academies Pr; 2011. Google Scholar - 34.
Bauer DC . Clinical practice. Calcium supplements and fracture prevention. N Engl J Med. 2013;369:1537-43. [PMID: 24131178] doi:10.1056/NEJMcp1210380 CrossrefMedlineGoogle Scholar - 35.
Romagnoli E ,Del Fiacco R ,Russo S ,et al . Secondary osteoporosis in men and women: clinical challenge of an unresolved issue. J Rheumatol. 2011;38:1671-9. [PMID: 21632675] doi:10.3899/jrheum.110030 CrossrefMedlineGoogle Scholar - 36.
Ryan CS ,Petkov VI ,Adler RA . Osteoporosis in men: the value of laboratory testing. Osteoporos Int. 2011;22:1845-53. [PMID: 20936403] doi:10.1007/s00198-010-1421-0 CrossrefMedlineGoogle Scholar - 37.
Jamal SA ,Leiter RE ,Bayoumi AM ,Bauer DC ,Cummings SR . Clinical utility of laboratory testing in women with osteoporosis. Osteoporos Int. 2005;16:534-40. [PMID: 15340801] CrossrefMedlineGoogle Scholar - 38.
Fink HA ,Litwack-Harrison S ,Taylor BC ,et al ;Osteoporotic Fractures in Men (MrOS) Study Group . Clinical utility of routine laboratory testing to identify possible secondary causes in older men with osteoporosis: the Osteoporotic Fractures in Men (MrOS) Study. Osteoporos Int. 2016;27:331-8. [PMID: 26458388] doi:10.1007/s00198-015-3356-y CrossrefMedlineGoogle Scholar - 39.
Watts NB ,Geusens P ,Barton IP ,Felsenberg D . Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res. 2005;20:2097-104. [PMID: 16294263] CrossrefMedlineGoogle Scholar - 40.
Cummings SR ,Karpf DB ,Harris F ,et al . Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002;112:281-9. [PMID: 11893367] CrossrefMedlineGoogle Scholar - 41.
Chen P ,Miller PD ,Delmas PD ,Misurski DA ,Krege JH . Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res. 2006;21:1785-90. [PMID: 17002571] CrossrefMedlineGoogle Scholar - 42. U.S. Department of Health and Human Services. Bone health and osteporosis: a report of the Surgeon General. 2004. Rockville, MD, U.S. Department of Health and Human Services, Office of the Surgeon General. Google Scholar
- 43.
Chung M ,Lee J ,Terasawa T ,Lau J ,Trikalinos TA . Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155:827-38. [PMID: 22184690]. doi:10.7326/0003-4819-155-12-201112200-00005 LinkGoogle Scholar - 44.
Siris ES ,Adler R ,Bilezikian J ,et al . The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int. 2014;25:1439-43. [PMID: 24577348] doi:10.1007/s00198-014-2655-z CrossrefMedlineGoogle Scholar - 45.
Wright NC ,Saag KG ,Dawson-Hughes B ,Khosla S ,Siris ES . The impact of the new National Bone Health Alliance (NBHA) diagnostic criteria on the prevalence of osteoporosis in the USA. Osteoporos Int. 2017;28:1225-1232. [PMID: 27966104] doi:10.1007/s00198-016-3865-3 CrossrefMedlineGoogle Scholar - 46.
MacLean C ,Newberry S ,Maglione M ,et al . Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2008;148:197-213. [PMID: 18087050] LinkGoogle Scholar - 47.
Wells GA ,Cranney A ,Peterson J ,et al . Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008:CD001155. [PMID: 18253985] doi:10.1002/14651858.CD001155.pub2 CrossrefMedlineGoogle Scholar - 48.
Cummings SR ,Black DM ,Thompson DE ,et al . Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077-82. [PMID: 9875874] CrossrefMedlineGoogle Scholar - 49.
McClung MR ,Geusens P ,Miller PD ,et al ;Hip Intervention Program Study Group . Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344:333-40. [PMID: 11172164] CrossrefMedlineGoogle Scholar - 50.
McClung MR ,Boonen S ,Törring O ,et al . Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res. 2012;27:211-8. [PMID: 21976367] doi:10.1002/jbmr.536 CrossrefMedlineGoogle Scholar - 51.
Schousboe JT ,Ensrud KE . Diagnostic criteria for osteoporosis should not be expanded. Lancet Diabetes Endocrinol. 2015;3:236-8. [PMID: 25797770] doi:10.1016/S2213-8587(15)00050-9 CrossrefMedlineGoogle Scholar - 52.
Qaseem A ,Forciea MA ,McLean RM ,Denberg TD ;Clinical Guidelines Committee of the American College of Physicians . Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med. 2017;166:818-839. [PMID: 28492856]. doi:10.7326/M15-1361 LinkGoogle Scholar - 53.
Moyer VA ;U.S. Preventive Services Task Force . Menopausal hormone therapy for the primary prevention of chronic conditions: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;158:47-54. [PMID: 23090711] LinkGoogle Scholar - 54.
Chapurlat RD ,Palermo L ,Ramsay P ,Cummings SR . Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial. Osteoporos Int. 2005;16:842-8. [PMID: 15580479] CrossrefMedlineGoogle Scholar - 55.
Sarkar S ,Mitlak BH ,Wong M ,et al . Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res. 2002;17:1-10. [PMID: 11771654] CrossrefMedlineGoogle Scholar - 56.
Bell KJ ,Hayen A ,Macaskill P ,et al . Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data. BMJ. 2009;338:b2266. [PMID: 19549996] doi:10.1136/bmj.b2266 CrossrefMedlineGoogle Scholar - 57.
Schousboe JT ,Bauer DC . Clinical use of bone turnover markers to monitor pharmacologic fracture prevention therapy. Curr Osteoporos Rep. 2012;10:56-63. [PMID: 22286411] doi:10.1007/s11914-011-0091-y CrossrefMedlineGoogle Scholar - 58.
Boudreau DM ,Yu O ,Balasubramanian A ,et al . A survey of women's awareness of and reasons for lack of postfracture osteoporotic care. J Am Geriatr Soc. 2017. [PMID: 28422273] doi:10.1111/jgs.14921 CrossrefMedlineGoogle Scholar - 59.
Khan AA ,Morrison A ,Kendler DL ,et al ;International Task Force on Osteonecrosis of the Jaw . Case-based review of osteonecrosis of the jaw (ONJ) and application of the international recommendations for management from the International Task Force on ONJ. J Clin Densitom. 2017;20:8-24. [PMID: 27956123] doi:10.1016/j.jocd.2016.09.005 CrossrefMedlineGoogle Scholar - 60.
Adler RA ,El-Hajj Fuleihan G ,Bauer DC ,et al . Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31:16-35. [PMID: 26350171] doi:10.1002/jbmr.2708 CrossrefMedlineGoogle Scholar - 61.
Shane E ,Burr D ,Abrahamsen B ,et al . Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29:1-23. [PMID: 23712442] doi:10.1002/jbmr.1998 CrossrefMedlineGoogle Scholar - 62.
Black DM ,Rosen CJ . Clinical Practice. Postmenopausal Osteoporosis. N Engl J Med. 2016;374:254-62. [PMID: 26789873] doi:10.1056/NEJMcp1513724 CrossrefMedlineGoogle Scholar - 63.
Gedmintas L ,Solomon DH ,Kim SC . Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res. 2013;28:1729-37. [PMID: 23408697] doi:10.1002/jbmr.1893 CrossrefMedlineGoogle Scholar - 64.
Dell RM ,Adams AL ,Greene DF ,et al . Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res. 2012;27:2544-50. [PMID: 22836783] doi:10.1002/jbmr.1719 CrossrefMedlineGoogle Scholar - 65.
Ott SM . Long-term bisphosphonates: primum non nocere. Menopause. 2016;23:1159-1161. [PMID: 27676636] CrossrefMedlineGoogle Scholar - 66.
Black DM ,Schwartz AV ,Ensrud KE ,et al ;FLEX Research Group . Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296:2927-38. [PMID: 17190893] CrossrefMedlineGoogle Scholar - 67.
Bauer DC ,Schwartz A ,Palermo L ,et al . Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. JAMA Intern Med. 2014;174:1126-34. [PMID: 24798675] doi:10.1001/jamainternmed.2014.1232 CrossrefMedlineGoogle Scholar - 68.
Black DM ,Reid IR ,Boonen S ,et al . The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012;27:243-54. [PMID: 22161728] doi:10.1002/jbmr.1494 CrossrefMedlineGoogle Scholar - 69.
Anastasilakis AD ,Yavropoulou MP ,Makras P ,et al . Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment. Eur J Endocrinol. 2017;176:677-683. [PMID: 28283537] doi:10.1530/EJE-16-1027 CrossrefMedlineGoogle Scholar - 70.
Aubry-Rozier B ,Gonzalez-Rodriguez E ,Stoll D ,Lamy O . Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports. Osteoporos Int. 2016;27:1923-5. [PMID: 26510845] doi:10.1007/s00198-015-3380-y CrossrefMedlineGoogle Scholar - 71.
Lee DR ,Ettinger B ,Chandra M ,Hui RL ,Lo JC . Changing Patterns in Oral Bisphosphonate Initiation in Women between 2004 and 2012 [Letter]. J Am Geriatr Soc. 2017;65:656-658. [PMID: 28152162] doi:10.1111/jgs.14723 CrossrefMedlineGoogle Scholar
Author, Article, and Disclosure Information
Authors:
Kristine E. Ensrud,
From the University of Minnesota and Veterans Affairs Health Care System, Minneapolis, Minnesota; and the University of California, Los Angeles, California.
CME Objective: To review current evidence for screening, prevention, diagnosis, treatment for fracture prevention, and practice improvement of osteoporosis.
Funding Source: American College of Physicians.
Acknowledgment: The authors thank E. Michael Lewiecki, author of the previous version of this In the Clinic.
With the assistance of additional physician writers, the editors of Annals of Internal Medicine develop In the Clinic using MKSAP and other resources of the American College of Physicians.
In the Clinic does not necessarily represent official ACP clinical policy. For ACP clinical guidelines, please go to https://www.acponline.org/clinical_information/guidelines/.
Disclosures: Dr. Ensrud, ACP Contributing Author, reports personal fees from from Merck Sharpe & Dohme, outside the submitted work; Dr. Crandall, ACP Contributing Author, has disclosed no conflicts of interest. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M17-1218.
Editors' Disclosures: Christine Laine, MD, MPH, Editor in Chief, reports that she has no financial relationships or interests to disclose. Darren B. Taichman, MD, PhD, Executive Deputy Editor, reports that he has no financial relationships or interests to disclose. Cynthia D. Mulrow, MD, MSc, Senior Deputy Editor, reports that she has no relationships or interests to disclose. Deborah Cotton, MD, MPH, Deputy Editor, reports that she has no financial relationships or interest to disclose. Jaya K. Rao, MD, MHS, Deputy Editor, reports that she has stock holdings/options in Eli Lilly and Pfizer. Sankey V. Williams, MD, Deputy Editor, reports that he has no financial relationships or interests to disclose. Catharine B. Stack, PhD, MS, Deputy Editor for Statistics, reports that she has stock holdings in Pfizer and Johnson & Johnson.
Submit a Comment
Contributors must reveal any conflict of interest. Comments are moderated. Please see our information for authorsregarding comments on an Annals publication.
*All comments submitted after October 1, 2021 and selected for publication will be published online only.